Spiros Malandrakis, senior alcoholic drinks analyst at Euromonitor International, explains why AB InBev’s bid was more of an account-inspired deal than a consumer trend-based one.
Andrew Holland, European and U.S. beverage research analyst at Societe Generale, explains why stakeholders want SABMiller to keep AB InBev's offer on the table.
Despite economic uncertainties, M&A targets in Asia totaled $770.9 billion, overtaking Europe as the second most active region, after the U.S.
Trian, the $13 billion activist hedge fund run by Nelson Peltz, will later this morning unveil a roughly $2.5 billion investment in General Electric, according to people familiar with the fund's plans.
British tech entrepreneur Mike Lynch says he will file a claim for $150 million in damages over allegations the U.S company made.
The market for distressed properties has spread from the housing market to the very heart of Sin City.
We want to go beyond Europe, says Mathias Dopfner, Axel Springer CEO, discussing its acquisition of Business Insider.
Jonny Forsyth, global drinks analyst at Mintel, says SABMiller could provide AB Inbev greater opportunities in different markets.
Spiros Malandrakis, alcoholic drinks analyst at Euromonitor International, discusses the takeover talk surrounding Anheuser-Busch InBev and SABMiller.
The DOJ complicates Halliburton's buyout of peer oilfield services company Baker Hughes.
In another consolidation move, XPO Logistics buys U.S. trucker Con-way for $3 billion.
Warren Buffett's Berkshire Hathaway buys 3.51 million shares of Phillips 66.
Paul Holland, Foundation Capital partner, weighs in on market action, and BlackBerry's deal to buy Good Technology.
Mylan shareholders back proposed Perrigo purchase.
Wells Fargo is the front-runner to buy GE's railcar financing unit. - Bloomberg
B&G Foods in late-stage talks to buy Green Giant from General Mills. - Reuters
Abbott denies FT speculation about a St. Jude's acquisition.
A Schlumberger-Cameron International deal may bring about an oil industry breakthrough.
Heartland Food Products Group gets a little sweeter after buying Splenda from Johnson and Johnson.
Michael Pearson, Valeant Pharma chairman & CEO, and Cindy Whitehead, Sprout Pharma CEO, discuss Valeant's acquisition of Sprout and its new female libido drug Addyi. With CNBC's Meg Tirrell.